Galcanezumab
Emgality (galcanezumab) is an antibody pharmaceutical. Galcanezumab was first approved as Emgality on 2018-09-27. It is used to treat cluster headache in the USA. It has been approved in Europe to treat migraine disorders. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1.
| Trade Name | Emgality |
|---|---|
| Common Name | Galcanezumab |
| Indication | cluster headache, migraine disorders |
| Drug Class | Monoclonal antibodies: humanized, neural indications |
